Last reviewed · How we verify
NCT04181177
Efficacy Study of Cosmetic Product on Xerosis Induced by Systemic Anticancer Treatments
trial testing Cosmetic product in Xerosis in 29 participants. Completed in 1 March 2022.
25 January 2022
Quick facts
| Lead sponsor | Pierre Fabre Dermo Cosmetique |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 29 |
| Start date | 19 February 2019 |
| Primary completion | 25 January 2022 |
| Estimated completion | 1 March 2022 |
| Sites | 4 locations across France |
Drugs / interventions tested
- Cosmetic product
Conditions studied
- Xerosis — all drugs for Xerosis →
Sponsor
Pierre Fabre Dermo Cosmetique — full company profile →
Who can join
Adults 18 to 75, any sex, with Xerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Xerosis is one of the most common adverse events in patients treated with new cancer therapies and chemotherapies, such as multi-kinase inhibitors and more specifically, immunological checkpoint inhibitors used in the treatment of several cancers. Xerosis appears as a result of a deterioration of the stratum corneum which results in a reduction of the hydric power of the skin. It reaches the trunk and limbs, with an incidence of 4-35%, and gradually disappears after the end of treatment. Preventive targeted educational action is essential before initiation of cancer treatment. Once the xerosis is installed, the management is based on the use of emollients to contribute to the hydric correction of the skin. In the case of inflammation or associated infection, the administration of topical corticosteroids and / or local or oral antibiotic therapy is prescribed. The aim of this study is to evaluate the efficacy of the cosmetic product (balm) on the improvement of xerosis induced by systemic anticancer treatments, in participants receiving targeted educational action compared to a control group. Clinical, biological and biometrological assessments will be performed to characterized the effects in both induced xerosis and associated signs and symptoms. Each group will include 40 participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04181177
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cosmetic product
Trials testing the same drug.
- NCT05756881 — Topical Palm Tocotrienols on Blemish-prone Skin · NA · terminated
- NCT05926791 — Photoprotective Effects of a SPF50+ Sunscreen on Skin Genotoxicity Induced by Repeated Chronic Outdoor Sun Exposure · completed
- NCT05171556 — IN-USE TOLERANCE STUDY UNDER DERMATOLOGICAL AND OPHTHALMOLOGICAL CONTROLS AND EFFICACY ASSESSMENT (Face Balm) · completed
- NCT05165420 — IN-USE TOLERANCE STUDY UNDER DERMATOLOGICAL AND OPHTHALMOLOGICAL CONTROLS AND EFFICACY ASSESSMENT (Face Cream) · completed
- NCT04873089 — Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin · completed
Other Pierre Fabre Dermo Cosmetique trials
Trials by the same sponsor.
- NCT07014007 — Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks · NA · not yet recruiting
- NCT07166484 — Assessment of the Effect of the Product RV2666C Formula LA2984 Compared to an Untreated Area With an Epidermally Ablated · not yet recruiting
- NCT06983561 — Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regard · recruiting
- NCT07341659 — Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subject · NA · active not recruiting
- NCT06800755 — Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04181177 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pierre Fabre Dermo Cosmetique
- Last refreshed: 28 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04181177.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing